Singapore markets closed

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1430-0.0021 (-1.45%)
At close: 04:00PM EDT
0.1437 +0.00 (+0.49%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.58M
Enterprise value 15.18M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)7.81
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 3-95.31%
S&P500 52-week change 326.49%
52-week high 35.6000
52-week low 30.0810
50-day moving average 30.1227
200-day moving average 31.3522

Share statistics

Avg vol (3-month) 314.55M
Avg vol (10-day) 36.11M
Shares outstanding 539.04M
Implied shares outstanding 639.04M
Float 839.03M
% held by insiders 10.19%
% held by institutions 11.08%
Shares short (30 Apr 2024) 44.04M
Short ratio (30 Apr 2024) 40.22
Short % of float (30 Apr 2024) 410.34%
Short % of shares outstanding (30 Apr 2024) 410.34%
Shares short (prior month 28 Mar 2024) 4658.9k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 308 May 2019
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 314 Nov 2022

Financial highlights

Fiscal year

Fiscal year ends 30 Jun 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-112.61%
Return on equity (ttm)-329.00%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -10.57M
Net income avi to common (ttm)-10.77M
Diluted EPS (ttm)-5.2200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)772k
Total cash per share (mrq)0.02
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.63
Book value per share (mrq)-1.02

Cash flow statement

Operating cash flow (ttm)-6.77M
Levered free cash flow (ttm)-6.16M